AI assistant
BridgeBio Pharma, Inc. — Director's Dealing 2025
Mar 21, 2025
30604_dirs_2025-03-21_1a6e0be5-18d3-4326-b0e0-c9832180b38e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2025-03-19
Reporting Person: Apuli Maricel (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-03-19 | Common Stock | A | 23660 | — | Acquired | 148665 | Direct |
Footnotes
F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/16th of the underlying shares on May 16, 2025, and as to 1/16th of the underlying shares each quarter thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.